Camber Pharmaceuticals recalls
FDA enforcement reports naming Camber Pharmaceuticals Inc as the recalling firm.
- Recall reports
- 5
- Class I (serious)
- 1
- Most recent report
- May 17, 2023
- May 17, 2023Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured fo…Drug · Camber Pharmaceuticals Inc.Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.Class I
- Dec 21, 2022Lacosamide Oral Solution, USP, CV, 10mg/mL, packaged in 200 mL bottle, Rx Only, Manufac…Drug · Camber Pharmaceuticals, IncFailed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid contentClass III
- Mar 27, 2019Losartan Potassium Tablets USP, 25 mg, Rx only, a) 90 count (NDC 31722-700-90), b) 500…Drug · Camber Pharmaceuticals IncCGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredientClass II
- Mar 27, 2019Losartan Potassium Tablets USP, 50 mg, Rx only, a) 30 count (NDC 31722-701-30), b) 90 c…Drug · Camber Pharmaceuticals IncCGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredientClass II
- Mar 27, 2019Losartan Potassium Tablets USP, 100 mg, Rx only, a) 30 count (NDC 31722-702-30), b) 90…Drug · Camber Pharmaceuticals IncCGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredientClass II